Moleculin announced the exercise of warrants that will generate $8.3 million in gross proceeds. This financing method enables the biotech company to secure capital from previous investors while minimizing immediate share dilution. Moleculin continues to focus on its lead asset, annamycin, in its oncology clinical programs.
Tom Lee stated that the Supreme Court’s decision to remove certain tariffs imposed during the Trump administration could help alleviate inflation, which may create an environment for the Federal Reserve to consider rate cuts. With […]
Stable coins have recently reached a market size comparable to that of Layer 1 (L1) blockchain networks and decentralized finance (DeFi) platforms combined. This milestone highlights the growing significance of stable coins in the cryptocurrency […]
A Canadian individual was robbed of cryptocurrency through an ATM kiosk, prompting recovery efforts that unfortunately led to another scam attempt. This incident highlights the increasing prevalence of cryptocurrency-related crimes, as criminals exploit vulnerabilities in […]